Abstract
Inflammation is an important pathogenic mechanism in chronic heart failure (HF). The perpetuation of the inflammatory response in this syndrome may result either from excessive activation of proinflammatory cascades or disturbances in the resolution of inflammation. However, although cardiovascular research has extensively investigated the proinflammatory processes involved in chronic HF pathophysiology, the mechanisms responsible for inflammation resolution in this disease remain largely disregarded. The resolving response is currently considered an active process involving specific effectors that limit the progression of inflammation and promote tissue regeneration. This article aims at reviewing the major classes of lipid mediators of inflammation resolution, their cardiovascular, metabolic and renal protective effects that might putatively delay the onset and progression of chronic HF, and their therapeutic modulation. Furthermore, it also aims to emphasize the importance of adopting therapeutic strategies that stimulate the resolution of inflammation in chronic HF.
Keywords: Heart failure, resolution of inflammation, proresolving lipid mediators, cardiovascular/metabolic and renal protection, therapeutic modulation.
Current Drug Targets
Title:Resolving Inflammation in Heart Failure: Novel Protective Lipid Mediators
Volume: 17 Issue: 10
Author(s): Marta Reina-Couto, Luís Vale, Jorge Carvalho, Paulo Bettencourt, António Albino-Teixeira and Teresa Sousa
Affiliation:
Keywords: Heart failure, resolution of inflammation, proresolving lipid mediators, cardiovascular/metabolic and renal protection, therapeutic modulation.
Abstract: Inflammation is an important pathogenic mechanism in chronic heart failure (HF). The perpetuation of the inflammatory response in this syndrome may result either from excessive activation of proinflammatory cascades or disturbances in the resolution of inflammation. However, although cardiovascular research has extensively investigated the proinflammatory processes involved in chronic HF pathophysiology, the mechanisms responsible for inflammation resolution in this disease remain largely disregarded. The resolving response is currently considered an active process involving specific effectors that limit the progression of inflammation and promote tissue regeneration. This article aims at reviewing the major classes of lipid mediators of inflammation resolution, their cardiovascular, metabolic and renal protective effects that might putatively delay the onset and progression of chronic HF, and their therapeutic modulation. Furthermore, it also aims to emphasize the importance of adopting therapeutic strategies that stimulate the resolution of inflammation in chronic HF.
Export Options
About this article
Cite this article as:
Reina-Couto Marta, Vale Luís, Carvalho Jorge, Bettencourt Paulo, Albino-Teixeira António and Sousa Teresa, Resolving Inflammation in Heart Failure: Novel Protective Lipid Mediators, Current Drug Targets 2016; 17 (10) . https://dx.doi.org/10.2174/1389450117666160101121135
DOI https://dx.doi.org/10.2174/1389450117666160101121135 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
GDF11 Attenuated ANG II-Induced Hypertrophic Cardiomyopathy and Expression of ANP, BNP and Beta-MHC Through Down- Regulating CCL11 in Mice
Current Molecular Medicine Neonatal Ultrasound in Transport
Current Pediatric Reviews Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients
Current Cancer Therapy Reviews Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Synergistic Effect of the Combination of Novel Suberoylanilide Hydroxamic Acid Derivatives with Cisplatin on Anti-proliferation of Human Cancer Cells
Medicinal Chemistry Increased Neuronal Injury in Transgenic Mice with Neuronal Overexpression of Human Cyclooxygenase-2 is reversed by Hypothermia and Rofecoxib Treatment
Current Neurovascular Research Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
Current Vascular Pharmacology Current Status of Renal Arterial Endovascular Interventions
Current Hypertension Reviews Post-Wortmannin Era: Novel Phosphoinositide 3-Kinase Inhibitors with Potential Therapeutic Applications
Current Enzyme Inhibition The Role of Phospholipase D Enzyme(s) in Modulating Cell Signaling: Implications for Cancer Drug Development
Current Bioactive Compounds Purinergic (P2) Receptor Control of Lower Genitourinary Tract Function and New Avenues for Drug Action: An Overview
Current Pharmaceutical Design Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk Assessment and Clinical Management
Cardiovascular & Hematological Disorders-Drug Targets Transactivation of EGFR by G Protein-Coupled Receptor in the Pathophysiology of Intimal Hyperplasia
Current Vascular Pharmacology Acute Kidney Injury in Pediatric Heart Failure
Current Cardiology Reviews Editorial (Thematic Issue: Novel Inflammatory Biomarkers in Cardiovascular Disease: From Molecular Mechanisms to Therapeutic Targets (Part-II))
Current Medicinal Chemistry Link between Metabolic Syndrome and Insulin Resistance
Current Vascular Pharmacology Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Medicinal Chemistry Cilostazol in the Management of Atherosclerosis
Current Vascular Pharmacology CYLD-Mediated Signaling and Diseases
Current Drug Targets The Meaning of Different Forms of Structural Myocardial Injury, Immune Response and Timing of Infarct Necrosis and Cardiac Repair
Current Vascular Pharmacology